title: ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients.
abstract: Systemic multiagent hemotherapy has been used to treat aggressive forms of primary cutaneous T-cell lymphomas (CTCL) with controversial results. Our objective was to retrospectively assess efficacy and toxicity of ESHAP (etoposide, cisplatin, high-dose aracytine, methylprednisolone) in patients with advanced CTCL. A total of 11 patients with aggressive primary CTCL, treated with the ESHAP protocol between 1995 and 2002, were studied. Two patients achieved complete remissions lasting 30+ and 6+ months, seven had partial remissions of short duration, one had stable disease and one experienced disease progression. ESHAP was poorly tolerated because of prolonged myelosuppression (91%) and infectious complications (82%). Our results suggest that ESHAP has a poor risk/benefit ratio in advanced CTCL because of the low number of complete remissions, the short duration of partial remissions and its high-grade toxicity.
authors.affiliation: Service de Dermatologie 2, Hôpital Saint-Louis, Paris, France.
authors.forename: Amel
authors.initials: A
authors.lastname: Mebazaa
authors.forename: Alain
authors.initials: A
authors.lastname: Dupuy
authors.forename: Michel
authors.initials: M
authors.lastname: Rybojad
authors.forename: Frédéric
authors.initials: F
authors.lastname: Mouly
authors.forename: Isabelle
authors.initials: I
authors.lastname: Moulonguet
authors.forename: Marie-Dominique
authors.initials: MD
authors.lastname: Vignon-Pennamen
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Rivet
authors.forename: Anne
authors.initials: A
authors.lastname: Janin
authors.forename: Celeste
authors.initials: C
authors.lastname: Lebbé
authors.forename: Louis
authors.initials: L
authors.lastname: Dubertret
authors.forename: Patrice
authors.initials: P
authors.lastname: Morel
authors.forename: Hervé
authors.initials: H
authors.lastname: Bachelez
authors.forename: Pauline
authors.initials: P
authors.lastname: Brice
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000453:epidemiology; D002945:Cisplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D018450:Disease Progression; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D003561:Cytarabine; D005047:Etoposide; D002945:Cisplatin; D008775:Methylprednisolone